Please use this identifier to cite or link to this item:
|Title:||Cross-resistance of <i style="">Mycobacterium tuberculosis</i> isolates among streptomycin, kanamycin and amikacin|
|Abstract:||Seventy-four streptomycin (SM)-resistant <i style="">M. tuberculosis</i> clinical isolates were subjected to cross-resistance drug testing against two major aminoglycosides, kanamycin (KM) and amikacin (AMK). Among them, 15 clinical isolates (20.3%) were resistant to both KM and AMK. Fifteen (80%) of 19 KM-resistant isolates were AMK-resistant. Fifteen SM, KM, and AMK resistant isolates harbored <i style="">rrs</i> mutation, but only two had <i style="">rrs</i> and <i style="">rpsL</i> double mutations. Low-level SM resistance was associated with <i style="">rpsL</i> mutation, whereas high-level SM resistance was linked to <i style="">rrs</i> mutation.|
|Appears in Collections:||IJEB Vol.47(06) [June 2009]|
Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.